No photo of Edmond Kwan

View Scopus Profile

Edmond Kwan

Dr

20152024
If you made any changes in Pure these will be visible here soon.

Projects 2017 2024

Application of a multi-gene prostate circulating tumour DNA (ctDNA) panel in men with metastatic hormone- sensitive prostate cancer (mHSPC)

Southey, M., Kwan, E., Fettke, H. & Azad, A.

ANZUP Cancer Trials Group

4/09/18 → 3/09/19

Project: Research

A randomised phase II trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastic castration resistant prostate cancer (ANZUP1603). TheraP Study

Kwan, E.

6/02/18 → 5/02/23

Project: Research

A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD)

Kwan, E.

2/10/18 → 1/10/23

Project: Research

A phase 2, open label, 2Arm, response rate study of talazoparib in men with DNA repair defects and metastatic castration resistant prostate cancer who previously received taxane based chemotherapy and progressed on at least 1 novel hormonal agent

Kwan, E.

21/04/17 → 28/11/23

Project: Research

A Phase 1/2, Open-Label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with MEDI4736 and MEDI0680 Monotherapy in Subjects with Select Advanced Malignancies

Kwan, E.

3/12/18 → 2/12/23

Project: Other

A Phase II, Randomised, Multi-Centre Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-Metastatic Castration-Resistant Prostate Cancer

Kwan, E.

4/01/19 → 3/01/24

Project: Research

A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC)

Kwan, E.

4/01/19 → 3/01/24

Project: Research

ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Kwan, E.

28/02/19 → 27/02/24

Project: Research

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations

Kwan, E.

25/03/19 → 24/03/24

Project: Research